Related Experiment Video
Updated: Aug 18, 2026
Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
Effects of prostaglandin E1 on the progression of aristolochic acid nephropathy
Dong Sun1, Jiang-min Feng, Yan-ling Zhao
1Department of Nephropathy, the First Affiliated Hospital, China Medical University, Shenyang 110001. sundgf@163.com
Objective:
To investigate the effects of prostaglandin E1 (PGE1) on the progression of aristolochic acid nephropathy (AAN).
Methods:
Twenty-four patients diagnosed as AAN with serum creatinine (Scr) between 1.5 mg/dL and 4 mg/dL during September 2001 to August 2003 were randomly divided into 2 groups. All patients had ingested long dan xie gan wan containing aristolochic acid (0.219 mg/g) for at least 3 months. Twelve patients were injected with Alprostadil (10 microg/d for 10 days in one month, summing up to 6 months). Except for PGE1, the other therapy was same in both groups. Renal function was assessed using reciprocal serum creatinine levels (1/Scr).
Results:
The level of Scr an d serum hemoglobin (Hgb) was similar in both groups prior to therapy. During follow-up, 1/Scr levels in PGE1 group were significantly higher than control group (P < 0.01), and Hgb levels in PGE1 group were significantly increased compared with control (P < 0.05).
Conclusion:
PGE1 can slow the progression of renal failure and increase Hgb level of AAN patient.
